05:00 AM EDT, 07/13/2026 (MT Newswires) -- Ondine Biomedical (OBI.L) said Monday it revised the timeline for results of its Lantern phase 3 study in the US evaluating its antibiotic nasal photodisinfection technology. The results are now expected within six weeks following recent guidance from the life sciences company's independent data management and statistical advisers. The technology, branded as Steriwave outside the US, is intended to reduce surgical site infections. The study's primary endpoint and success criteria are unchanged, Ondine added.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.